High Potency Topical Corticosteroids for Severe Dermatitis and Psoriasis

Initial Treatment Strategy

The American Academy of Dermatology recommends using high potency topical corticosteroids (class 1-2) such as clobetasol propionate 0.05% for 2-4 weeks maximum for severe psoriasis and dermatitis, applied twice daily to thick plaques, with mandatory transition to intermittent use or lower potency agents for long-term management under physician supervision 1, 2
Class 1 (ultra-high potency) agents like clobetasol propionate 0.05% or halobetasol propionate 0.05% are indicated for thick, chronic plaques and severe disease, achieving 58-92% efficacy rates 3
Class 2 (high potency) agents including betamethasone dipropionate 0.05% achieve 68-74% efficacy and may be used when class 1 agents are not required 3
The American Academy of Dermatology advises avoiding high potency steroids on the face, intertriginous areas, genitals, and forearms where skin atrophy risk is highest; use class 5-7 (low potency) agents in these locations 1, 2, 4

After achieving control with high potency agents, transition to intermittent use rather than continuous application to minimize side effects 3
An alternative approach is to switch to the least potent agent that maintains disease control for patients requiring continuous treatment 3
Consider steroid-sparing agents such as calcineurin inhibitors (tacrolimus, pimecrolimus) for facial and intertriginous areas after initial control 1
Mandatory regular clinical review with no unsupervised repeat prescriptions for high potency agents is required 5, 6, 7
Class 1-2 (very potent/potent) preparations require dermatological supervision according to established guidelines 5, 6, 7
Extended use beyond 12 weeks may be considered only under careful physician supervision, though evidence for this is limited (Level III) 1, 2

Skin atrophy, striae, telangiectasia, purpura, and folliculitis are the most common local adverse effects 1, 2, 4
The face, intertriginous areas, and chronically treated areas (especially forearms) are at greatest risk for developing these complications 1, 2
Rebound phenomenon can occur with abrupt withdrawal, though frequency is variable; gradual tapering of frequency after clinical improvement is recommended 1

Intralesional triamcinolone acetonide up to 20 mg/mL can be used every 3-4 weeks for nonresponding or very thick lesions on glabrous skin, scalp, nails, palms, and soles 1, 2
Topical agents can be combined with phototherapy or systemic agents to enhance efficacy in patients improving but with residual active disease 3

Approximately 400g of topical agent covers the entire body surface of an average adult when used twice daily for 1 week 3
No more than 100g of moderately potent preparation should be applied monthly for general use 5, 6, 7
Some patients who fail one topical agent may respond to another; trial alternative agents before escalating to more aggressive management 5, 6, 7
Periods each year should employ alternative treatments to prevent continuous high potency steroid exposure 5, 6, 7